Zai Lab to present Phase 1/1b healthy-volunteer data for atopic disease antibody ZL-1503 at ACAAI 2026
Bitget2026/10/14 11:00- Zai Lab flagged first clinical data for ZL-1503, a bispecific antibody for atopic diseases, from its Phase 1/1b healthy-volunteer trial.
- Results have not been presented yet; the initial readout is scheduled for the ACAAI 2026 meeting on Nov. 13.
- The update will cover how the drug behaved in the body, early biomarker effects, and initial safety and immunogenicity observations.
- Zai Lab positioned the program as a potentially longer-acting approach aimed at reducing itch and inflammation in IL-13- and IL-31-driven conditions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley bullish on Apple (AAPL.US): First foldable iPhone Duo sees strong pre-orders, with delivery period reaching a 14-week ten-year record
Apple (AAPL.US)'s first foldable smartphone, the iPhone Duo, demonstrated strong early demand on its first day of pre-orders.
Algorand tops post-quantum race with 2.7M secure transfers- Will it rally ALGO?
OCP Summit sends out a full-stack collaboration signal, GF Securities: Semiconductor pullback creates a great buying opportunity, optimistic about Nvidia, Marvell, and the CPU supply chain
GF Securities analysts attended the OCP Global Summit held in San Jose last week. The conference reflected that hyperscale cloud providers are shifting towards full-stack collaborative design.
Black Monday Fears Fade as Nasdaq Futures Rally After Friday Selloff
Crypto prices
More
